DexCom Inc. (NASDAQ:DXCM)’s share price shot up 7% during mid-day trading on Tuesday . The stock traded as high as $86.35 and last traded at $83.68, with a volume of 1,764,711 shares changing hands. The stock had previously closed at $78.19.

A number of brokerages recently weighed in on DXCM. BTIG Research restated a “buy” rating and set a $92.00 price objective on shares of DexCom in a research report on Tuesday. Leerink Swann restated an “outperform” rating and set a $90.00 price objective on shares of DexCom in a research report on Wednesday. Canaccord Genuity restated a “buy” rating and set a $95.00 price objective on shares of DexCom in a research report on Wednesday, July 13th. Zacks Investment Research upgraded DexCom from a “sell” rating to a “hold” rating in a research report on Tuesday. Finally, Jefferies Group restated a “buy” rating and set a $98.00 price objective (up previously from $90.00) on shares of DexCom in a research report on Friday, July 15th. Three analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $94.62.

The firm’s market cap is $7.06 billion. The stock’s 50-day moving average price is $75.80 and its 200 day moving average price is $68.61.

DexCom (NASDAQ:DXCM) last released its earnings results on Wednesday, April 27th. The medical device company reported ($0.23) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.20) by $0.03. During the same quarter in the previous year, the company posted ($0.17) earnings per share. The company earned $116.20 million during the quarter, compared to analyst estimates of $110.37 million. The firm’s revenue was up 59.6% compared to the same quarter last year. On average, analysts predict that DexCom Inc. will post ($0.35) earnings per share for the current fiscal year.

In related news, SVP Jeffrey Moy sold 4,557 shares of the stock in a transaction on Wednesday, June 29th. The stock was sold at an average price of $80.00, for a total value of $364,560.00. Following the transaction, the senior vice president now owns 76,333 shares of the company’s stock, valued at $6,106,640. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Andrew K. Balo sold 5,000 shares of the stock in a transaction on Wednesday, July 13th. The shares were sold at an average price of $80.12, for a total value of $400,600.00. Following the completion of the transaction, the executive vice president now directly owns 134,979 shares in the company, valued at approximately $10,814,517.48. The disclosure for this sale can be found here.

Several hedge funds and institutional investors recently made changes to their positions in the stock. Trexquant Investment LP bought a new position in shares of DexCom during the fourth quarter worth about $1,515,000. I.G. Investment Management LTD. boosted its position in shares of DexCom by 149.7% in the fourth quarter. I.G. Investment Management LTD. now owns 23,852 shares of the medical device company’s stock worth $1,953,000 after buying an additional 14,300 shares during the period. Principal Financial Group Inc. boosted its position in shares of DexCom by 13.2% in the fourth quarter. Principal Financial Group Inc. now owns 79,782 shares of the medical device company’s stock worth $6,534,000 after buying an additional 9,277 shares during the period. Rhumbline Advisers boosted its position in shares of DexCom by 0.5% in the fourth quarter. Rhumbline Advisers now owns 88,844 shares of the medical device company’s stock worth $7,276,000 after buying an additional 480 shares during the period. Finally, Swiss National Bank boosted its position in shares of DexCom by 0.9% in the fourth quarter. Swiss National Bank now owns 105,600 shares of the medical device company’s stock worth $8,649,000 after buying an additional 900 shares during the period.

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.